Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + estramustine + carboplatin
- Development stage
- Unknown
- Lead developer
- SCRI Development Innovations
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination chemotherapy regimen, consisting of paclitaxel, estramustine, and carboplatin, was evaluated by SCRI Development Innovations, LLC for the treatment of castration-resistant prostate cancer (CRPC), also known as hormone-refractory prostate cancer. Paclitaxel is a taxane that stabilizes microtubules, preventing cell division and inducing apoptosis. Estramustine is a conjugate of estradiol and nitrogen mustard that interferes with microtubule dynamics by binding to microtubule-associated proteins (MAPs). Carboplatin is a platinum-based antineoplastic agent that induces DNA cross-linking, inhibiting DNA synthesis and transcription. The regimen was specifically investigated in a Phase II trial to optimize the dosing and schedule of carboplatin when administered alongside weekly paclitaxel and low-dose estramustine to improve efficacy and reduce toxicity in advanced prostate cancer patients.
- Other names
- Weekly Paclitaxel, Estramustine, and CarboplatinTEC regimenPaclitaxel, Estramustine, and Carboplatin
02
Targets
DNATUBB (Tubulin (alpha and beta subunits))ER (Estrogen receptor)
Beyond the preview
Go deeper on paclitaxel + estramustine + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + estramustine + carboplatin.